Oppenheimer Reiterates “Outperform” Rating for Gain Therapeutics (NASDAQ:GANX)

Oppenheimer reaffirmed their outperform rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report released on Tuesday morning, Benzinga reports. Oppenheimer currently has a $9.00 price objective on the stock.

A number of other equities analysts also recently issued reports on GANX. Chardan Capital reissued a buy rating and issued a $6.00 price target on shares of Gain Therapeutics in a research note on Wednesday, March 27th. HC Wainwright reiterated a buy rating and set a $9.00 target price on shares of Gain Therapeutics in a report on Monday, April 1st.

Gain Therapeutics Price Performance

GANX opened at $3.03 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.59 and a current ratio of 3.59. The stock has a market capitalization of $49.15 million, a PE ratio of -1.77 and a beta of 0.43. The stock’s 50 day moving average price is $3.97 and its 200-day moving average price is $3.44. Gain Therapeutics has a 52-week low of $2.00 and a 52-week high of $5.65.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. On average, equities research analysts predict that Gain Therapeutics will post -1.22 EPS for the current year.

Insider Buying and Selling

In other Gain Therapeutics news, Director Jeffrey Scott Riley acquired 30,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the completion of the acquisition, the director now owns 30,000 shares in the company, valued at $115,800. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 11.00% of the stock is currently owned by insiders.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.